Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The NUVASCULAR HARBOR Occlusion Device EU Study

NCT07900464 is registered in ClinicalTrials.gov with Nuvascular Inc as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07900464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
The NUVASCULAR HARBOR Occlusion Device EU Study
Lead sponsor
Nuvascular Inc
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 26, 2026
Completion date
December 18, 2028
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

intracranial arterial aneurysm

Arms

As registered; 1 arm.

  • HARBOR Occlusion Device ExperimentalHARBOR Occlusion Device

    Participants with eligible intracranial aneurysms will receive endovascular treatment with the HARBOR Occlusion Device. The device is delivered through a microcatheter and implanted in the target aneurysm. Participants will undergo protocol-specified clinical, neurological, and imaging assessments through the 1-year follow-up visit.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Complete Aneurysm Occlusion Without Retreatment, Recurrent Subarachnoid Hemorrhage, or Significant Parent Artery Stenosis. 1 year after treatment (10-14 months)

    Proportion of participants with complete aneurysm occlusion and no retreatment, recurrent subarachnoid hemorrhage, or significant parent artery stenosis (\>50%) at 1 year after treatment. Participants must meet all criteria to be counted as an effectiveness success.

  • Proportion of Participants with Nonaccidental Death Cause or Major Stroke From treatment through 1 year after treatment (10-14 months).

    Proportion of participants with death from any nonaccidental cause or major stroke within 30 days after treatment, or major ipsilateral stroke or death due to a neurological cause from day 31 through 1 year after treatment. Major stroke is defined as an ischemic or hemorrhagic stroke resulting in an increase of at least 4 points on the NIH Stroke Scale.

Lead sponsor's other trials

Nuvascular Inc, most recent start first.